Enveric stockholders approve conditional reverse stock split to avoid Nasdaq delisting

Enveric Biosciences, Inc.

Stockholders authorized board to implement reverse stock split between 1:5 and 1:50 if Nasdaq issues bid price delisting determination before Jan 28, 2026.
Reverse stock split proposal passed with 881,471 votes for, 301,346 against, 23,681 abstentions.
All six director nominees elected; Michael D. Webb received 175,763 votes for, 155,118 withheld (875,617 broker non-votes).
Say-on-pay proposal passed with 253,560 votes for, 75,850 against, 1,471 abstentions.
Auditor ratification of CBIZ CPAs P.C. passed with 1,082,606 votes for, 115,857 against, 8,035 abstentions.

item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.